1179 Understanding the impact of magrolimab on red blood cell …
Nov 5, 2024 · Background Magrolimab is a monoclonal IgG4 antibody that binds to CD47, blocking the CD47-SIRPα checkpoint interaction. Previous clinical trials demonstrated on-target anemia mitigated …
Results: Combination treatment of magroli-mab with AZA resulted in a tolerable anemia that correlated with rapid, near complete loss of CD47 from RBCs, but not WBCs. The initial 1mg/kg priming dose …
MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red …
Oct 1, 2022 · Azacitidine 75 mg/m 2 days 1-7 (each 28-day cycle). Results: Treatment with magrolimab+azacitidine resulted in tolerable anemia that correlated with rapid, near-complete loss of …
RBC Toxicity Mitigation in Anti-CD47 Antibody Cancer Therapies and ...
They found a priming dose of CD47 antibody therapy decreases RBC clearance through inhibition of phagocytic capacity of macrophages, and provides red blood cells protection against subsequent …
RBC-Specific CD47 Pruning Confers Protection and Underlies the ...
Nov 29, 2018 · Notably, these clinical and pre-clinical findings have been RBC-specific and have not precluded anti-tumor efficacy. The loss of CD47 on RBCs after the priming dose also suggests that …
The First-in-Class Anti-CD47 Antibody Magrolimab + Azacitidine Is …
The priming dose regimen helped to mitigate anemia, and many patients were able to decrease their red blood cell (RBC) transfusion requirements while on therapy. Hemoglobin decreased by a mean of 0.4 …
A Novel Affinity Engineered Anti-CD47 Antibody With Improved ...
May 19, 2022 · High CD47 expression on normal cells among which RBCs, platelets and lymphocytes express elevated levels of CD47 led to significant toxicities (mainly thrombocytopenia, anemia, …
. The mechanism of removal of both red blood cells and platelets for patients on anti-CD47 therapy at this stage is still unclear. While anaemia is pre ent, indicators of haemolysis including increased bili …
developed and have shown activity in preclinical models of hematologic and solid tumors. Anemia is a common adverse event associated with anti-CD47 treatment, but mitigation strategiesdincluding use …
First-in-kind anti-CD47 antibody shows promise for MDS and AML ...
Jun 19, 2020 · Anemia from CD47 blockade was mitigated by the use of a priming dose of magrolimab coupled to a maintenance-dose regimen, resulting in a mild hemoglobin drop on the first dose, which …
Here we report our experience of the red cell effects, impact on blood bank testing and transfusion management in a Phase I trial of the humanised anti-CD47 monoclonal antibody Hu5F9-G4 in …